Literature DB >> 28644310

Predictors of Mortality in Cirrhosis Inpatients With Clostridium difficile Infection.

Elliot Z Smith1, Patrick G Northup, Curtis K Argo.   

Abstract

BACKGROUND: Clostridium difficile is a bacterial pathogen associated with significant morbidity and mortality in patients with cirrhosis. GOALS: Our primary aim is to identify variables that are predictive of poor outcomes in cirrhosis patients with C. difficile infection (CDI). We also aim to further characterize the risk factors for developing CDI and risk of mortality in this patient population. STUDY: A total of 200 subjects with a diagnosis of cirrhosis and CDI were matched to 200 cirrhosis inpatients without CDI. The groups were compared to evaluate variables associated with decreased survival for cirrhosis inpatients with CDI as well as risk factors for developing CDI.
RESULTS: Cirrhosis patients with CDI were more frequently prescribed antibiotics during their hospitalization (P=0.002) and cared for in an intensive care unit (ICU) (P<0.001). Preadmission proton pump inhibitor and spontaneous bacterial peritonitis (SBP) prophylactic antibiotic use were not significantly different between the 2 cohorts. CDI subjects had an increased 30-day mortality (44% vs. 28.5%, P=0.034), however overall mortality was not significantly different (P=0.2). The multivariable logistic regression model demonstrated an increased 30-day and overall mortality in the CDI population was independently associated with albumin <3 g/dL and ICU admission.
CONCLUSIONS: C. difficile infections are associated with a significant increase in 30-day mortality, but not overall mortality. Risk factors of ICU admission and antibiotic exposure were associated with the diagnosis of CDI in cirrhosis patients. Hypoalbuminemia and ICU admission were found to be strong predictors of increased mortality in cirrhosis patients with CDI.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 28644310     DOI: 10.1097/MCG.0000000000000868

Source DB:  PubMed          Journal:  J Clin Gastroenterol        ISSN: 0192-0790            Impact factor:   3.062


  7 in total

1.  Is it reasonable to perform Fecal Microbiota Transplantation for recurrent Clostridium difficile Infection in patients with liver cirrhosis?

Authors:  M Olmedo; E Reigadas; M Valerio; S Vázquez-Cuesta; J A Pajares; A Matilla; P Muñoz; E Bouza
Journal:  Rev Esp Quimioter       Date:  2019-03-08       Impact factor: 1.553

Review 2.  Clostridioides difficile Infection in Liver Cirrhosis: A Concise Review.

Authors:  Yuanbin Liu; Mingkai Chen
Journal:  Can J Gastroenterol Hepatol       Date:  2022-06-07

Review 3.  Hypoalbuminemia as Surrogate and Culprit of Infections.

Authors:  Christian J Wiedermann
Journal:  Int J Mol Sci       Date:  2021-04-26       Impact factor: 5.923

4.  Outcomes of Clostridioides difficile Infection in Patients With Liver Cirrhosis: A Nationwide Study.

Authors:  Abubaker O Abdalla; Sailaja Pisipati; Mohamed Elnaggar; Mohit Rishi; Rajkumar Doshi; Nageshwara Gullapalli
Journal:  Gastroenterology Res       Date:  2020-04-22

Review 5.  Clostridium difficile Infection in Liver Cirrhosis Carries a Higher Risk of Mortality: A Comprehensive Literature Review.

Authors:  Veeraraghavan Meyyur Aravamudan; Shahab R Khan; Ikram Hussain
Journal:  Cureus       Date:  2019-08-22

6.  Low serum albumin and the risk of hospitalization in COVID-19 infection: A retrospective case-control study.

Authors:  Roshan Acharya; Dilli Poudel; Aakash Patel; Evan Schultz; Michael Bourgeois; Rishi Paswan; Scott Stockholm; Macylen Batten; Smita Kafle; Amanda Atkinson; Hafiz Sarwar
Journal:  PLoS One       Date:  2021-04-30       Impact factor: 3.240

7.  Incidence and Risk Factors of Recurrent Clostridioides difficile Infection in Patients With Cirrhosis.

Authors:  Parkpoom Phatharacharukul; Russell D Purpura; Devika Gandhi; Huiping Xu; Katie Bickett-Burkhart; Naga Chalasani; Monika Fischer; Eric S Orman
Journal:  Clin Transl Gastroenterol       Date:  2020-07       Impact factor: 4.396

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.